Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle

Autonomic Neuroscience: Basic and Clinical

Volumn 150, Issue 1-2, 2009, Pages 27-32

  Dab, Houcine ^a,b   Hachani, Rafik ^a   Hodroj, Wassim ^b   Sakly, Mohsen ^a   Bricca, Giampiero ^b   Kacem, Kamel ^a  

^a Struggle and Prevention   (Tunisia)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Angiotensin II AT1 receptor antagonist; Left ventricle; MMP 2; MMP 9; PAI 1; Sympathectomy; t PA

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART LEFT VENTRICLE; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYMPATHECTOMY; SYSTOLIC BLOOD PRESSURE; ZYMOGRAPHY;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; GENE EXPRESSION REGULATION; GUANETHIDINE; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 69349100922     PISSN: 15660702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autneu.2009.04.002     Document Type: Article

References (36)

1. Balt J.C., Mathy M.J., Nap A., Pfaffendorf M., and van Zwieten P.A. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J. Cardiovasc. Pharmacol. 38 1 (2001) 141-148 Jul
2. Brouwers-Ceiler D.L., Nelissen-Vrancken H.J., Smits J.F., and De Mey J.G. The influence of angiotensin II-induced increase in aortic wall mass on compliance in rats in vivo. Cardiovasc. Res. 33 2 (1997) 478-484 Feb
3. Brown N.J., Agirbasli M.A., Williams G.H., Litchfield W.R., and Vaughan D.E. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32 6 (1998) 965-971 Dec
4. Brown N.J., Bradford J., Wang Z., Lea W., Ma L., Ma J., Vaughan D.E., and Fogo A.B. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency. Kidney Int 72 1 (2007) 72-81 Jul
5. Burnstock G. Purinergic nerves. Pharmacol. Rev. 24 3 (1972) 509-581 Sep
6. Burnstock G. Sympathetic purinergic transmission in small blood vessels. Trends Pharmacol. Sci. 9 4 (1988) 116-117 Apr
7. Cao J.M., Fishbein M.C., Han J.B., Lai W.W., Lai A.C., Wu T.J., Czer L., Wolf P.L., Denton T.A., Shintaku I.P., Chen P.S., and Chen L.S. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 101 16 (2000) 1960-1969 Apr 25
8. Cerutti C., Kurdi M., Bricca G., Hodroj W., Paultre C., Randon J., and Gustin M.P. Transcriptional alterations in the left ventricle of three hypertensive rat models. Physiol. Genomics 27 3 (2006) 295-308 Nov 27
9. Dendorfer A., Raasch W., Tempel K., and Dominiak P. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res. Cardiol. 93 (1998) 24-29
10. Dwyer K.W., Provenzano P.P., Muir P., Valhmu W.B., and Vanderby Jr. R. Blockade of the sympathetic nervous system degrades ligament in a rat MCL model. J. Appl. Physiol. 96 2 (2004) 711-718 Feb
11. Erdem Y., Usalan C., Haznedaroǧlu I.C., Altun B., Arici M., Yasavul U., Turgan C., and Caǧlar S. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. J. Hypertens. 12 11 Pt 1 (1999) 1071-1076 Nov
12. Felmeden D.C., and Lip G.Y. The renin-angiotensin-aldosterone system and fibrinolysis. J. Renin. Angiotensin Aldosterone Syst. 1 3 (2000) 240-244 Sep
13. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90 3 (2002) 251-262 Feb 22
14. Goodfield N.E., Newby D.E., Ludlam C.A., and Flapan A.D. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 99 23 (1999) 2983-2985 Jun 15
15. Hao Z., Jiang X., Sharafeih R., Shen S., Hand A.R., Cone R.E., and O'Rourke J. Stimulated release of tissue plasminogen activator from artery wall sympathetic nerves: implications for stress-associated wall damage. Stress 8 2 (2005) 141-149 Jun
16. Johnson B.M. The use of radioactive microspheres to compare the effects of hydralazine, guanethidine and SK & F 24260 on the redistribution of cardiac output in anaesthetized rabbits. Br. J. Pharmacol. 55 3 (1975) 393-402 Nov
17. Johnson Jr. E.M., Macia R.A., and Yellin T.O. Marked difference in the susceptibility of several species to guanethidine-induced chemical sympathectomy. Life Sci. 20 1 (1977) 107-112 Jan 1
18. Lijnen H.R. Elements of the fibrinolytic system. Ann. N. Y. Acad. Sci. 936 (2001) 226-236
19. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 11 (2006) 1696-1701 May 1
20. Milner P., Bodin P., and Burnstock G. Long-term guanethidine sympathectomy suppresses flow-induced release of ATP and endothelin from endothelial cells isolated from adult rat aorta. J. Vasc. Res. 33 2 (1996) 139-145 Mar-Apr
21. Miner E.C., and Miller W.L. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin. Proc. 81 1 (2006) 71-76 Jan
22. O'Rourke J., Jiang X., Hao Z., Cone R.E., and Hand A.R. Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J. Neurosci. Res. 79 6 (2005) 727-733 Mar 15
23. Otowa K., Takamura M., Murai H., Maruyama M., Nakano M., Ikeda T., Kobayashi D., Ootsuji H., Okajima M., Furushou H., Yuasa T., Takata S., and Kaneko S. Altered interaction between plasminogen activator inhibitor type 1 activity and sympathetic nerve activity with aging. Circ. J. 72 3 (2008) 458-462 Mar
24. Perlini S., Palladini G., Ferrero I., Tozzi R., Fallarini S., Facoetti A., Nano R., Clari F., Busca G., Fogari R., and Ferrari A.U. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46 5 (2005) 1213-1218 Nov
25. Raasch W., Dominiak P., Ziegler A., and Dendorfer A. Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension 44 3 (2004) 346-351 Sep
26. Ralevic V., and Burnstock G. Effects of short- and long-term sympathectomy on vasoconstrictor responses of the rat mesenteric arterial bed. Br. J. Pharmacol. 119 7 (1996) 1347-1354 Dec
27. Reinhardt D., Sigusch H.H., Hensse J., Tyagi S.C., Körfer R., and Figulla H.R. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 5 (2002) 525-530 Nov
28. Rocha F.L., Carmo E.C., Roque F.R., Hashimoto N.Y., Rossoni L.V., Frimm C., Anéas I., Negrão C.E., Krieger J.E., and Oliveira E.M. Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. Am. J. Physiol. Heart Circ. Physiol. 293 6 (2007) H3575-H3583 Dec
29. Rodríguez J.A., Orbe J., and Páramo J.A. Metalloproteases, vascular remodeling and atherothrombotic syndromes. Rev. Esp. Cardiol. 60 9 (2007) 959-967 Sep
30. Seeland U., Selejan S., Engelhardt S., Müller P., Lohse M.J., and Böhm M. Interstitial remodeling in beta1-adrenergic receptor transgenic mice. Basic Res. Cardiol. 102 2 (2007) 183-193 Mar
31. Senzaki H., Paolocci N., Gluzband Y.A., Lindsey M.L., Janicki J.S., Crow M.T., and Kass D.A. beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ. Res. 86 7 (2000) 807-815 Apr 14
32. Simon G., and Csiky B. Effect of neonatal sympathectomy on the development of structural vascular changes in angiotensin II-treated rats. J. Hypertens. 16 1 (1998) 77-84 Jan
33. Supowit S.C., Ethridge R.T., Zhao H., Katki K.A., and Dipette D.J. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am. J. Physiol. Heart Circ. Physiol. 289 3 (2005) H1169-H1175 Sep
34. Wang W., and Ma R. Cardiac sympathetic afferent reflexes in heart failure. Heart Fail. Rev. 5 1 (2000) 57-71 Mar
35. Zannad F., and Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail. Rev. 10 1 (2005) 71-78 Jan
36. Zucker I.H., Wang W., Pliquett R.U., Liu J.L., and Patel K.P. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann. N. Y. Acad. Sci. 940 (2001) 431-443 Jun